Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (128,503)	$ (179,894)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,948	13,714
Amortization and impairment of internal-use software	4,586	2,514
Stock-based compensation expense	41,063	74,840
Gain on disposal of property and equipment	(55)	(5)
Loss on disposition of Lemonaid Health Limited	0	2,026
Other operating activities	0	(504)
Changes in operating assets and liabilities:
Accounts receivable, net (includes related party amounts of $1 and $19 for the six months ended September 30, 2024 and 2023, respectively)	2,878	396
Inventories	(2,381)	(4,733)
Deferred cost of revenue	(950)	(406)
Prepaid expenses and other current assets	(174)	(2,433)
Operating lease right-of-use assets	3,790	3,529
Other assets	381	664
Accounts payable (includes related party amounts of $(3,809) and $(3,186) for the six months ended September 30, 2024 and 2023, respectively)	(5,063)	(3,951)
Accrued expenses and other current liabilities (includes related party amounts of $(4,822) and $4,993 for the six months ended September 30, 2024 and 2023, respectively)	1,899	(5,674)
Deferred revenue (includes related party amounts of $661 and $(11,753) for the six months ended September 30, 2024 and 2023, respectively)	(5,076)	(22,237)
Operating lease liabilities	(4,826)	(4,255)
Other liabilities	283	(65)
Net cash used in operating activities	(84,200)	(126,474)
Cash flows from investing activities:
Purchases of property and equipment	(566)	(715)
Proceeds from sale of property and equipment	159	5
Capitalized internal-use software costs	(3,449)	(4,758)
Net cash used in investing activities	(3,856)	(5,468)
Cash flows from financing activities:
Proceeds from exercise of stock options	58	473
Proceeds from issuance of common stock under employee stock purchase plan	331	1,411
Payments of deferred offering costs	(2)	(263)
Payments for taxes related to net share settlement of equity awards	(118)	(142)
Net cash provided by financing activities	269	1,479
Net decrease in cash, cash equivalents and restricted cash	(87,787)	(130,463)
Cash, cash equivalents and restricted cash—beginning of period	224,861	395,222
Cash, cash equivalents and restricted cash—end of period	137,074	264,759
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	85	26
Stock-based compensation capitalized for internal-use software costs	1,099	2,089
Reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the amounts shown in the condensed consolidated statements of cash flows above:
Cash and cash equivalents	126,601	256,386
Restricted cash, current	1,499	1,399
Restricted cash, noncurrent	8,974	6,974
Total cash, cash equivalents and restricted cash	$ 137,074	$ 264,759